ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’)

Read also

Myeloma

Myeloma treatment HDP-101 put on FDA fast track

Evotec Announces Progress

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Evotec Announces Progress

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Tylenol (paracetamol)

Tylenol (paracetamol) fights autism claims, slams proposed FDA warning label as 'unsupported' by science